83 related articles for article (PubMed ID: 15616686)
1. New drug targets in inflammation and immunomodulation.
Norman P
Drug News Perspect; 1998 Sep; 11(7):442-7. PubMed ID: 15616686
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. New drug targets in inflammation and immunomodulation.
Norman P
Drug News Perspect; 2001 Aug; 14(6):373-84. PubMed ID: 12813600
[TBL] [Abstract][Full Text] [Related]
4. The impact of new technologies on drug design.
Norman P
Drug News Perspect; 2001 Mar; 14(2):123-8. PubMed ID: 12819803
[TBL] [Abstract][Full Text] [Related]
5. Chemokines in infection and inflammatory disease--the Royal Society of Medicine.
Zheng R
IDrugs; 1999 Mar; 2(3):225-7. PubMed ID: 16160931
[TBL] [Abstract][Full Text] [Related]
6. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
7. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
8. Medicinal Chemistry--XVth EFMC International Symposium. New technologies in drug discovery. 6-10 September 1998, Edinburgh, Scotland, UK.
Buckle DR
IDrugs; 1998 Dec; 1(8):860-2. PubMed ID: 16196472
[TBL] [Abstract][Full Text] [Related]
9. New drugs for the treatment of advanced-stage diffuse large cell lymphomas.
O'Connor OA; Hamlin P
Semin Hematol; 2006 Oct; 43(4):251-61. PubMed ID: 17027659
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
Lu H; Tonge PJ
Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
[TBL] [Abstract][Full Text] [Related]
11. Chemoproteomics-driven drug discovery: addressing high attrition rates.
Hall SE
Drug Discov Today; 2006 Jun; 11(11-12):495-502. PubMed ID: 16713900
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and bioactions of novel stable mimetics of lipoxins and aspirin-triggered lipoxins.
Petasis NA; Akritopoulou-Zanze I; Fokin VV; Bernasconi G; Keledjian R; Yang R; Uddin J; Nagulapalli KC; Serhan CN
Prostaglandins Leukot Essent Fatty Acids; 2005; 73(3-4):301-21. PubMed ID: 16098719
[TBL] [Abstract][Full Text] [Related]
13. Chemokines as novel therapeutic targets for inflammatory bowel disease.
Nishimura M; Kuboi Y; Muramoto K; Kawano T; Imai T
Ann N Y Acad Sci; 2009 Sep; 1173():350-6. PubMed ID: 19758172
[TBL] [Abstract][Full Text] [Related]
14. Integrated expressional analysis: application to the drug discovery process.
Ilyin SE; Horowitz D; Belkowski SM; Xin H; Eckardt AJ; Darrow AL; Chen C; Maley D; D'Andrea M; Plata-Salamán CR; Derian CK
Methods; 2005 Nov; 37(3):280-8. PubMed ID: 16308157
[TBL] [Abstract][Full Text] [Related]
15. Expediting drug discovery: recent advances in fast medicinal chemistry--optimization of hits and leads.
Edwards PJ; Allart B; Andrews MJ; Clase JA; Menet C
Curr Opin Drug Discov Devel; 2006 Jul; 9(4):425-44. PubMed ID: 16889227
[TBL] [Abstract][Full Text] [Related]
16. The Role of Bioinformatics in Identifying and Defining Potential Drug Targets.
Norman P
Drug News Perspect; 2002 May; 15(4):253-256. PubMed ID: 12677210
[TBL] [Abstract][Full Text] [Related]
17. Structural proteomics in drug discovery.
Tari LW; Rosenberg M; Schryvers AB
Expert Rev Proteomics; 2005 Aug; 2(4):511-9. PubMed ID: 16097885
[TBL] [Abstract][Full Text] [Related]
18. Detection of potential enzyme targets by metabolic modelling and optimization: application to a simple enzymopathy.
Vera J; Curto R; Cascante M; Torres NV
Bioinformatics; 2007 Sep; 23(17):2281-9. PubMed ID: 17586544
[TBL] [Abstract][Full Text] [Related]
19. The 7 TM G-protein-coupled receptor target family.
Jacoby E; Bouhelal R; Gerspacher M; Seuwen K
ChemMedChem; 2006 Aug; 1(8):761-82. PubMed ID: 16902930
[TBL] [Abstract][Full Text] [Related]
20. Histamine H3 and H4 receptors as novel drug targets.
Tiligada E; Zampeli E; Sander K; Stark H
Expert Opin Investig Drugs; 2009 Oct; 18(10):1519-31. PubMed ID: 19758107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
